Results 61 to 70 of about 15,943 (150)

Clinical Significance of Endoscopic Improvement at 6 Months in Patients With Ulcerative Colitis Treated With Ustekinumab: A Retrospective Real‐world Analysis

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Objectives Ustekinumab (UST), an anti‐interleukin‐12/23 p40 monoclonal antibody, has emerged as an effective therapeutic option for patients with moderate to severe ulcerative colitis (UC). However, early predictors of long‐term treatment response remain unclear.
Hiromu Morikubo, Minoru Matsuura, Haruka Komatsu, Takeshi Fujima, Ryota Ogihara, Noriaki Oguri, Tatsuya Mitsui, Daisuke Saito, Mari Hayashida, Jun Miyoshi, Tadakazu Hisamatsu   +10 more
wiley   +1 more source

The Sicilian network of biological therapy in inflammatory bowel disease: preliminary data on efficacy . [PDF]

, 2017
Background and aim: The monitoring of appropriateness and costs of biological therapy in Inflammatory bowel disease (IBD) is a relevant need. We aimed to evaluate appropriateness, efficacy and safety of biological therapy in IBD in Sicily through a web ...
Accomando S., Belluardo N., Calandruccio G., Cappello M., Carroccio A., Citrano M., Cottone M., Di Mitri R., Fries W., Genova S., Inserra G., Macaluso F. S., Magnano A., Magrì G., Orlando A., Orlando R., Pellegrino S., Privitera A. C., Renna S., Rizzuto G., Romano C., Scarpulla G., Siringo S., Trovatello N., Vassallo R., Ventimiglia M., Vinci E.   +26 more
core   +1 more source

Utility of Hybrid Endoscopy Combining Small‐Bowel Capsule Endoscopy and Conventional Ileocolonoscopy in Crohn's Disease

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Objectives To evaluate the safety and utility of hybrid endoscopy for whole‐bowel assessment in Crohn's disease (CD) and its role in treatment decision‐making. Methods This single‐center retrospective study included 125 patients with CD in clinical remission (Crohn's Disease Activity Index ≤150) who underwent hybrid endoscopy between February ...
Takahiro Ito, Kohei Matsunaga, Yuya Ohno, Muchir Shi, Atsuo Maemoto   +4 more
wiley   +1 more source

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. [PDF]

, 2013
ObjectiveEtrolizumab (rhuMAb β7, anti-β7, PRO145223) is a humanised monoclonal antibody targeting the β7 subunit of the heterodimeric integrins α4β7 and αEβ7, which are implicated in leucocyte migration and retention in ulcerative colitis (UC).
Baumgart, Daniel C, Bressler, Brian, Danilenko, Dimitri, Egen, Jackson, Fedorak, Richard N, Hommes, Daan W, Keir, Mary, Luca, Diana, Mansfield, John C, O'Byrne, Sharon, Rutgeerts, Paul J, Schreiber, Stefan, Sturm, Andreas, Tang, Meina, Visich, Jennifer, Wei, Xiaohui, Williams, Marna   +16 more
core  

Traditional Chinese medicine combination therapy for patients with steroid-dependent ulcerative colitis: study protocol for a randomized controlled trial [PDF]

, 2017
SPIRIT 2013 Checklist: recommended items to address in a clinical trial protocol and related documents.
Hong Shen, Jia Jia, Kai Zheng, Lei Zhu, Lu Zhang, Yuelin Lu, Zhaofeng Shen   +6 more
core   +3 more sources

Efficacy and Safety of Second‐Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID

United European Gastroenterology Journal, Volume 14, Issue 3, April 2026.
ABSTRACT Background and Aims Vedolizumab has become the preferred first‐line advanced therapy in ulcerative colitis (UC). However, the optimal second‐line treatment following vedolizumab failure remains unclear. We aimed to evaluate the effectiveness and safety of second‐line therapies after first‐line vedolizumab.
Louis Calméjane, Catherine Reenaers, Claire Gay, Aurélien Amiot, Alexandre Nuzzo, Lucine Vuitton, Calina Atanasiu, Carmen Stefanescu, Romain Altwegg, Lucas Guillo, Mélanie Serrero, Guillaume Bouguen, Maria Nachury, Guillaume Le Cosquer, Xavier Roblin, Vered Abitbol, Nassim Hammoudi, Marion Simon, Mathurin Fumery, Guillaume Savoye, Alban Benezech, Maryan Cavicchi, Maeva Charkaoui, Anthony Buisson, Bénédicte Caron, Benoît Coffin, Sophie Geyl, Félix Goutorbe, Marianne Hupé, Mathias Vidon, David Laharie, Julien Kirchgesner, Mathieu Uzzan, on behalf ofthe GETAID‐AFTER‐VEDO Study Group   +33 more
wiley   +1 more source

Helminths in the gastrointestinal tract 1 as modulators of immunity and pathology [PDF]

, 2017
Helminth parasites are highly prevalent in many low- and middle-income countries, in which inflammatory bowel disease and other immunopathologies are less frequent than in the developed world.
Fleming, John O., Maizels, Richard, Varyani, Fumi   +2 more
core   +1 more source

Intestinal Ultrasound Transmural Healing Was Associated With Improved Long‐Term Outcomes Among Patients With Endoscopic Remission: Results of a Prospective Study

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 992-999, April 2026.
This a prospective study showing the benefit of intestinal ultrasound transmural healing on long term outcome among patient with partial and complete endoscopic healing in Crohn's disease. ABSTRACT Background STRIDE II guidelines recognise endoscopic healing as a main therapeutic target in Crohn's disease (CD).
Clara Yzet, Amélie Plancke, Franck Brazier, Lucien Grados, Elise Derval, Louise Ghilardi, Momar Diouf, Adrien Ollier, Mathurin Fumery   +8 more
wiley   +1 more source

Host gene–microbiome interactions: molecular mechanisms in inflammatory bowel disease [PDF]

, 2017
Recent studies have identified links between host genetic variants and microbial recognition of the microbiome. Defects in host–microbiome interactions in individuals harboring inflammatory bowel disease risk alleles may result in imbalances of the ...
Chu, Hiutung
core   +2 more sources

Drug‐induced hypersensitivity syndrome followed by exacerbation of Crohn's disease

Pediatric Investigation, EarlyView.
Mei Kamidani, Ryo Tanaka, Hiroshi Oue, Risa Fukuda, Rena Hashimoto, Ichiro Takeuchi, Takako Yoshioka, Naoya Tonegawa, Akira Ishiguro, Katsuhiro Arai, Kazue Yoshida   +10 more
wiley   +1 more source